Extra Vaccine Halts Mumps Outbreak

A third dose of the MMR vaccine given during an intense outbreak appears to have provided herd-immunity to control the spread of the disease.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A transmission electron micrograph of mumps virionsWikimedia, Centers for Disease Control and PreventionGiving previously vaccinated children an additional dose of the measles, mumps, and rubella (MMR) vaccine helped to control an intense outbreak in a small, tight-knit religious community, according to researchers from the Centers for Disease Control and Prevention. The new study, published this week (November 5) in Pediatrics, suggests that the intervention provided a herd-immunity effect—where a significant part of a population with immunity to a particular pathogen acts as a firewall to protect the entire community by disrupting the chain of infection.

The researchers studied a mumps outbreak in an orthodox Jewish community in Orange County, New York, in late 2009 in which 400 children from three schools fell ill. Most of the children in the community had been vaccinated with the recommended 2 doses but a combination of large families and crowded schools overwhelmed that protection, the researchers say.

So a third vaccine was administered to children with no history of mumps in the outbreak. Shortly after this intervention, the number of new cases fell across all age groups by 19.6 percent. And they dropped even more dramatically—by 96 percent—in students aged 11 to 17, a group that had experienced more intense transmission.

This decline shortly after intervention suggests that a third dose of MMR vaccine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies